Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026)
Anaptysbio (ANAB) posted Depreciation & Amortization (CF) of $130000.0 for Q1 2026, down 0.76% on a QoQ basis from $131000.0 in Q4 2025, and down 10.96% year-over-year from $146000.0 in Q1 2025.
Anaptysbio (ANAB) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Anaptysbio's Depreciation & Amortization (CF) history runs 11 years deep, the most recent figure standing at $130000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 10.96% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $543000.0 (down 7.81% YoY) and the FY2025 annual result came in at $559000.0, down 7.76% from the prior year.
- Depreciation & Amortization (CF) was $130000.0 for Q1 2026 at Anaptysbio, down from $131000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $184000.0 in Q4 2022 and bottomed at $130000.0 in Q1 2026.
- A 5-year average of $154235.3 and a median of $158000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) gained 29.6% — and 2024, when it dropped 12.12%.
- Anaptysbio's Depreciation & Amortization (CF) stood at $184000.0 in 2022, then retreated by 10.33% to $165000.0 in 2023, then fell by 12.12% to $145000.0 in 2024, then fell by 9.66% to $131000.0 in 2025, then declined by 0.76% to $130000.0 in 2026.
- Business Quant data shows ANAB's Depreciation & Amortization (CF) at $130000.0 in Q1 2026, $131000.0 in Q4 2025, and $140000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |